• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray

According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company's Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, "Nasal Formulation of Metoclopramide") is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. … [Read more...] about Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray

Tiziana to develop intranasal foralumab for hemorrhagic stroke

Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement at one month post-dose. The company did not provide details of the study. The company recently … [Read more...] about Tiziana to develop intranasal foralumab for hemorrhagic stroke

GSK gives up exclusive license for use of Liquidia’s PRINT particle technology for inhaled formulations

Liquidia Corporation said that a new agreement will supersede its 2012 license agreement with GSK that gave GSK exclusive rights to develop certain inhaled formulations based on Liquidia's PRINT particle engineering technology. In 2015, GSK exercised an option giving it exclusive worldwide rights to develop PRINT formulations of inhaled therapies, with the exception … [Read more...] about GSK gives up exclusive license for use of Liquidia’s PRINT particle technology for inhaled formulations

PureIMS gets investment to fund development of its Levodopa Cyclops DPI

DPI developer PureIMS announced that it has closed an investment round that included Boost-UP Foundation, CardusoCapital, IMDS Medical Devices, and LinesBridge Pharma Group, with funds intended mostly to support development of a levodopa DPI based on the company's Cyclops pre-filled single use dry powder inhaler. The amount of the new investment was not specified. … [Read more...] about PureIMS gets investment to fund development of its Levodopa Cyclops DPI

Catalent to manufacture HRT’s RiVive naloxone nasal spray

Catalent and Harm Reduction Therapeutics (HRT) announced that they have signed a commercial supply agreement for the manufacture of HRT's RiVive intranasal naloxone. The news comes shortly after HRT said that it would receive an additional $9 million in funding from Purdue Pharma that would be used to prepare for possible commercialization of RiVive. The FDA … [Read more...] about Catalent to manufacture HRT’s RiVive naloxone nasal spray

Harm Reduction Therapeutics to get an additional $9 million from Purdue for development of RiVive naloxone nasal spray

According to Harm Reduction Therapeutics (HRT), the court handling the bankruptcy of Purdue Pharma has approved an additional $9 million in Purdue funds to be used by HRT to prepare for possible commercialization of RiVive intranasal naloxone. HRT notes that "neither Purdue nor any of its creditors will receive any revenues, royalties, or profits associated with … [Read more...] about Harm Reduction Therapeutics to get an additional $9 million from Purdue for development of RiVive naloxone nasal spray

Allermi raises $3.5 million for direct-to-consumer customized nasal spray

US start-up Allermi said that it has raised $3.5 million in a seed round led by Nelstone Ventures for "the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms." The company says that its nasal spray service is currently … [Read more...] about Allermi raises $3.5 million for direct-to-consumer customized nasal spray

Esteve Pharmaceuticals launches Inbrija levodopa DPI in Spain

According to Acorda Therapeutics, Esteve Pharmaceuticals has launched Acorda's Inbrija inhaled dry powder levodopa in Spain. Acorda announced the Spanish distribution deal with Esteve in July 2021. Inbrija DPI has been approved in Europe for the treatment of OFF periods in Parkinson’s disease since 2019.  Acorda President and CEO Ron Cohen said, "Today’s … [Read more...] about Esteve Pharmaceuticals launches Inbrija levodopa DPI in Spain

NeOnc Technologies announces plans to develop NEO100 intranasal perillyl alcohol for pediatric brain tumors

NeOnc Technologies has announced plans to develop its NEO100 intranasal perillyl alcohol for the treatment of high-grade gliomas in children. In 2016, NeOnc initiated a Phase 1/2a trial of NEO100 in adults with glioblastoma multiforme; according to clinicaltrials.gov, that study is expected to be completed in 2024. In 2020,the company published Phase 1 data for 12 … [Read more...] about NeOnc Technologies announces plans to develop NEO100 intranasal perillyl alcohol for pediatric brain tumors

Akorn files for bankruptcy, closes all US facilities

Akorn Pharmaceuticals has filed for Chapter 7 bankruptcy and closed all US facilities, including its manufacturing plant in Decatur, IL. A Decatur newspaper, the Herald Review, published a video of Akorn President and CEO Douglas Boothe informing workers on a Zoom call that the company would lay off all employees without any severance pay or insurance coverage as of … [Read more...] about Akorn files for bankruptcy, closes all US facilities

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews